Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim and contract research and development firm VTU Technology have renewed their global Pichia pastoris technology collaboration agreement.
Subscribe to our email newsletter
The agreement will give Boehringer access to VTU’s yield-enhancing Pichia pastoris expression platform to develop and manufacture therapeutic proteins.
The platform is based on VTU’s AOX1 promoter libraries and set of expression enhancing helper factors, several platform strains with different genetic backgrounds, elaborated cloning and transformation protocols, a high-throughput screening & cultivation regime combined with know-how in fermentation and downstream process development.
Currently, VTU Technology is offering a very broad and versatile technology platform available for Pichia pastoris protein production.
VTU will now be responsible for conducting the joint development program in its facilities, in close collaboration with researchers from both companies
Boehringer Ingelheim Process Science Austria executive director Georg Klima said: "We are excited about the continuation of our successful collaboration with VTU Technology. Together we established Pichia pastoris as innovative platform for the manufacture of biopharmaceuticals.
"With the renewal of our collaboration we will further expand our technological lead for Boehringer Ingelheim’s own development projects as well as for Boehringer Ingelheim BioXcellence customers globally."
VTU Technology Business Development head Dr Thomas Purkarthofer said: "The ongoing commitment of Boehringer Ingelheim in our technology collaboration underlines the skills and capabilities of our great team. We are very much looking forward to new exciting developments in this fruitful collaboration."
BioXcellence is the new brand for Boehringer’s biopharma contract development and manufacturing services and is capable of providing the entire production technology chain from DNA to fill and finish under one brand, through its facilities in Biberach, Germany; Vienna, Austria; Fremont, US; and Shanghai, China.
Image: Boehringer Ingelheim’s corporate headquarters in Ingelheim, Germany. Photo: courtesy of Boehringer Ingelheim GmbH.